Anti-VEGF therapies in diabetic retinopathy and diabetic macular edema

被引：0
作者：
Couzinet, Anne [1 ]
Mahieu, Laurence [1 ]
Pagot-Mathis, Veronique [1 ]
Mathis, Andre [1 ]
机构：
[1] CHU Rangueil, Serv Ophtalmol Pr Mathis, F-31054 Toulouse, France
来源：
CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION | 2009年 / 13卷 / 04期
关键词：
ENDOTHELIAL GROWTH-FACTOR; NEOVASCULARIZATION; BEVACIZUMAB; PEGAPTANIB; AVASTIN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：155 / 159
页数：5
相关论文
共 11 条
[1]   Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals [J].
Adamis, AP ;
Altaweel, M ;
Bressler, NM ;
Cunningham, ET ;
Davis, MD ;
Goldbaum, M ;
Gonzales, C ;
Guyer, DR ;
Katz, B ;
Patel, M .
OPHTHALMOLOGY, 2006, 113 (01) :23-28
[2]   VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS [J].
AIELLO, LP ;
AVERY, RL ;
ARRIGG, PG ;
KEYT, BA ;
JAMPEL, HD ;
SHAH, ST ;
PASQUALE, LR ;
THIEME, H ;
IWAMOTO, MA ;
PARK, JE ;
NGUYEN, HV ;
AIELLO, LM ;
FERRARA, N ;
KING, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) :1480-1487
[3]   A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema [J].
Cunningham, ET Jr ;
Adamis, AP ;
Altaweel, M ;
Aiello, LP ;
Bressler, NM ;
D'Amico, DJ ;
Goldbaum, M ;
Guyer, DR ;
Katz, B ;
Patel, M ;
Schwartz, SD .
OPHTHALMOLOGY, 2005, 112 (10) :1747-1757
[4]   Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema The Pan-American Collaborative Retina Study Group at 24 Months [J].
Fernando Arevalo, J. ;
Sanchez, Juan G. ;
Wu, Lihteh ;
Maia, Mauricio ;
Alezzandrini, Arturo A. ;
Brito, Miguel ;
Bonafonte, Sergio ;
Lujan, Silvio ;
Diaz-Llopis, Manuel ;
Restrepo, Natalia ;
Rodriguez, Francisco J. ;
Udaondo-Mirete, Patricia .
OPHTHALMOLOGY, 2009, 116 (08) :1488-1497
[5]   The Wisconsin epidemiologic study of diabetic retinopathy: XVII - The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes [J].
Klein, R ;
Klein, BEK ;
Moss, SE ;
Cruickshanks, KJ .
OPHTHALMOLOGY, 1998, 105 (10) :1801-1815
[6]   Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 [J].
Kleinman, Mark E. ;
Yamada, Kiyoshi ;
Takeda, Atsunobu ;
Chandrasekaran, Vasu ;
Nozaki, Miho ;
Baffi, Judit Z. ;
Albuquerque, Romulo J. C. ;
Yamasaki, Satoshi ;
Itaya, Masahiro ;
Pan, Yuzhen ;
Appukuttan, Binoy ;
Gibbs, Daniel ;
Yang, Zhenglin ;
Kariko, Katalin ;
Ambati, Balamurali K. ;
Wilgus, Traci A. ;
DiPietro, Luisa A. ;
Sakurai, Eiji ;
Zhang, Kang ;
Smith, Justine R. ;
Taylor, Ethan W. ;
Ambati, Jayakrishna .
NATURE, 2008, 452 (7187) :591-U1
[7]  
MASSIN PG, 2008, EVR SAT S SPONS NOV
[8]   Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy [J].
Oshima, Yusuke ;
Sakaguchi, Hirokazu ;
Gomi, Fumi ;
Tano, Yasuo .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (01) :155-158
[9]   Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage [J].
Spaide, Richard F. ;
Fisher, Yale L. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03) :275-278
[10]   Twelve-month safety of intravitreal injections of bevacizumab (Avastin®):: results of the Pan-American Collaborative Retina Study Group (PACORES) [J].
Wu, Lihteh ;
Martinez-Castellanos, Maria A. ;
Quiroz-Mercado, Hugo ;
Arevalo, J. Fernando ;
Berrocal, Maria H. ;
Farah, Michel E. ;
Maia, Mauricio ;
Roca, Jose A. ;
Rodriguez, Francisco J. .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2008, 246 (01) :81-87
12